Cue Biopharma
Jason Brown has worked in the pharmaceutical industry since 1998. Jason began their career at Formatech as a Research Associate II, conducting preformulation and formulation development activities for pre-clinical and marketable drugs. Jason then moved to Millennium Pharmaceuticals in 2001, where they served as a Research Investigator in the Formulation Sciences department. Jason'sresponsibilities included leading CMO site selection teams, managing drug product CMO activities for multiple programs, and leading internal and external cross-functional teams to manage DP manufacturing activities. In 2012, Jason joined AVEO Pharmaceuticals as Manager/Sr. Scientist in the Drug Product Technical Support department. Jason'sresponsibilities included managing all DP related activities on multiple programs, serving as a drug product representative on multiple CMC teams, and leading multiple cross-functional teams managing CMO and CRO activities. In 2014, they moved to Takeda Oncology as Sr Project Manager Biologics CMOs. Jason'srole included serving as the liaison between the Biologics CMC Group and contract manufacturing sites, coordinating timelines, setting milestones, actions and deliverables for projects, and organizing steering committee and technical meetings. Most recently, Jason has been the Director Drug Product and Supply Chain, CMC Technical Operations and Associate Director, CMC and External Manufacturing at Cue Biopharma since 2018.
Jason Brown attended the University of Massachusetts Lowell from 1993 to 1998, graduating with a Bachelor of Science in Clinical Lab Sciences, with a Chemistry Specialization.
Cue Biopharma
1 followers
Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.